Applied Genetic price target lowered to $15 from $20 at Wells Fargo. Wells Fargo analyst Jim lowered his price target for Applied Genetic to $15 from $20 following “disappointing” Phase 1/2 data for the XLRS gene therapy program. Overall, the analyst believes the results were expected, based on earlier updates, and should not be generalized to ongoing retinal gene therapy programs for XLRP and ACHM-B3 and ACHM-A3, where he continues to see greater likelihood of success in 2019. Birchenough reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.